Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer.
Carboplatin, a cisplatin analog without significant clinical nephrotoxicity, has been evaluated in the treatment of 56 patients with small cell lung carcinoma at a dose of 300-400 mg/m2 iv monthly in a phase II study. Twenty-three patients (41%) achieved a response, including five (9%) complete remissions. Of 30 previously untreated patients, 18 (60%) achieved a response, including three (10%) complete remissions. Median response duration was 4.5 months (range, 2-9). No nephrotoxicity was seen and hydration was not required. Nausea or vomiting occurred in only 24 patients (43%) and was rarely severe. Myelosuppression was dose-limiting: 20 patients (36%) developed leukopenia and eight (14%) developed thrombocytopenia, but leukopenic infections occurred in only three patients. Carboplatin is a very active new agent in the treatment of small cell lung cancer, with less toxicity and better tolerance than cisplatin. It merits further investigation in combination chemotherapy and against non-small cell lung cancer.
Smith
I E
IE
Harland
S J
SJ
Robinson
B A
BA
Evans
B D
BD
Goodhart
L C
LC
Calvert
A H
AH
Yarnold
J
J
Glees
J P
JP
Baker
J
J
Ford
H T
HT
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D016190:Carboplatin; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D014839:Vomiting / Q000139:chemically induced
D009944:Organoplatinum Compounds; D016190:Carboplatin